Download this “living” summary slideset covering new data from key studies in gynecologic cancers as they are presented at different conferences throughout 2022.
In this podcast episode, listen to Prof Isabelle Ray-Coquard, MD, PhD, and Ignace Vergote, MD, PhD, share their thoughts on trials of interest including novel HRD testing for ovarian cancer, OS results from ARIEL3, and QoL outcomes for rare nonepithelial ovarian cancers following chemotherapy.
In this podcast episode, listen to Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, discuss key updates for PARP inhibitor trials in ovarian cancer presented at the 2022 ESMO Congress, including the 7-year update from SOLO-1, final OS analyses for PAOLA-1, disease risk subgroup analysis from ATHENA-MONO, and OS results from ARIEL4.
In this podcast episode, listen to David Scott Miller, MD, FACOG, FACS, and Angeles Alvarez Secord, MD, MHSc, discuss key data for gynecologic cancers presented at the 2022 SGO annual meeting, including data for novel agents in ovarian and endometrial cancers, and practical insights on recent approvals for cervical cancer.
In this podcast episode, listen to Jubilee Brown, MD, and Elisabeth Diver, MD, discuss new data for gynecologic cancers presented at the 2022 ASCO Annual Meeting, including practical insights on how they plan to use the new findings to inform their practice and emerging data for novel agents in endometrial cancers, and practical insights on recent approvals for cervical cancer.
In this podcast episode, listen to Susana Banerjee, MBBS, MA, PhD, FRCP, and Mansoor Raza Mirza, MD, share their thoughts on trials of interest for ovarian and cervical cancer presented at the IGCS 2022 Annual Global Meeting, including results from the highly anticipated CALLA trial, final OS analyses for ARIEL3, outcomes by previous lines of therapy from SOLO3, and results from the retrospective NeCTuR trial of topotecan, paclitaxel, and bevacizumab in neuroendocrine cervix cancer.
In this commentary, expert faculty address frequently asked questions about integrating novel treatments for the management of patients with gynecologic cancers.
Two expert gynecologic oncologists answer frequently asked questions on the optimal use of new therapies in patients with endometrial, ovarian, and cervical cancer.
Two expert gynecologic oncologists discuss how to optimally use PARP inhibitors to treat patients with ovarian cancer.
Two experts in gynecologic cancers discuss important clinical trial updates, including chemoradiation, PARP inhibition, and checkpoint inhibitors.
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.